enGene participated in the Bladder Cancer Advocacy Network's Partners in Progress program and concluded its participation.
Published
Signal category
Partnerships
Quote
“our participation in the Bladder Cancer Advocacy Network's (BCAN) Partners in Progress program comes to a close”
— enGene team
Company
enGene
A biotechnology company aiming to mainstream non-viral genetic medicines.
- Industry
- Biotechnology Research
- Location
- Boston, US
- Company size
- 135 employees
enGene (Nasdaq: ENGN) is a clinical-stage biotechnology company mainstreaming non-viral genetic medicines that can be delivered locally to the site of disease—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. Founded in Canada, with a United States headquarters located in Boston, we are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes. To learn more about enGene visit our website: enGene.com. We are currently enrolling select patients with NMIBC in our LEGEND clinical trial. We have sites in the United States, Canada, Europe and the Asia-Pacific region. For more information, please visit TheLegendStudy.com.
Founded 1999